Multi-Drug Resistance (MDR) Antibiotics Market in China 2021
The multi-drug resistance (MDR) antibiotics market in China in terms of revenue is set to grow by US$ 3 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 9.7% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for multi-drug resistance (MDR) antibiotics. The China multi-drug resistance (MDR) antibiotics market is segmented on the basis of type. By type, it is categorized into daptomycin, linezolid, teicoplanin, and tigecycline.
The report has profiled some of the key players of the market such as Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., North China Pharmaceutical Company Ltd., Pfizer Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the multi-drug resistance (MDR) antibiotics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: daptomycin, linezolid, teicoplanin, and tigecycline
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China multi-drug resistance (MDR) antibiotics market
Pinpoint growth sectors and trends for investment
Understand what the future of the multi-drug resistance (MDR) antibiotics market in China looks like
Identify the competitive landscape and window of opportunity
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for multi-drug resistance (MDR) antibiotics. The China multi-drug resistance (MDR) antibiotics market is segmented on the basis of type. By type, it is categorized into daptomycin, linezolid, teicoplanin, and tigecycline.
The report has profiled some of the key players of the market such as Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., North China Pharmaceutical Company Ltd., Pfizer Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the multi-drug resistance (MDR) antibiotics market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: daptomycin, linezolid, teicoplanin, and tigecycline
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China multi-drug resistance (MDR) antibiotics market
Pinpoint growth sectors and trends for investment
Understand what the future of the multi-drug resistance (MDR) antibiotics market in China looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. MULTI-DRUG RESISTANCE (MDR) ANTIBIOTICS MARKET BY TYPE
4.1 Daptomycin
4.2 Linezolid
4.3 Teicoplanin
4.4 Tigecycline
5. COMPANY PROFILES
5.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
5.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
5.3 North China Pharmaceutical Company Ltd.
5.4 Pfizer, Inc.
5.5 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.6 Zhejiang Medicine Co., Ltd.
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. MULTI-DRUG RESISTANCE (MDR) ANTIBIOTICS MARKET BY TYPE
4.1 Daptomycin
4.2 Linezolid
4.3 Teicoplanin
4.4 Tigecycline
5. COMPANY PROFILES
5.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
5.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
5.3 North China Pharmaceutical Company Ltd.
5.4 Pfizer, Inc.
5.5 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.6 Zhejiang Medicine Co., Ltd.
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
